Mostrar el registro sencillo del ítem

dc.contributor.authorMarrugal, Ángela
dc.contributor.authorFerrer, Irene
dc.contributor.authorPastor, Maria Dolores
dc.contributor.authorOjeda, Laura
dc.contributor.authorQuintanal-Villalonga, Alvaro 
dc.contributor.authorCarnero, Amancio
dc.contributor.authorMolina-Pinelo, Sonia
dc.contributor.authorPaz Ares, Luis Gonzaga 
dc.date.accessioned2019-08-12T09:38:41Z
dc.date.available2019-08-12T09:38:41Z
dc.date.issued2019-07-31
dc.identifier.citationCells. 2019;8(8).es_ES
dc.identifier.issn2073-4409es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8205
dc.description.abstractHeat shock protein 90 (HSP90) is an important chaperone in lung adenocarcinoma, with relevant protein drivers such as EGFR (epidermal growth factor receptor) and EML4-ALK (echinoderm microtubule-associated protein-like protein4 fused to anaplastic lymphoma kinase) depending on it for their correct function, therefore HSP90 inhibitors show promise as potential treatments for lung adenocarcinoma. To study responses to its inhibition, HSP90 was pharmacologically interrupted by geldanamycin and resorcinol derivatives or with combined inhibition of HSP90 plus HSP70 in lung adenocarcinoma cell lines. Two-dimensional electrophoresis was performed to identify proteomic profiles associated with inhibition which will help to understand the biological basis for the responses. HSP90 inhibition resulted in altered protein profiles that differed according the treatment condition studied. Results revealed 254 differentially expressed proteins after treatments, among which, eukaryotic translation initiation factor3 subunit I (eIF3i) and citrate synthase demonstrated their potential role as response biomarkers. The differentially expressed proteins also enabled signalling pathways involved in responses to be identified; these included apoptosis, serine-glycine biosynthesis and tricarboxylic acid cycle. The proteomic profiles identified here contribute to an improved understanding of HSP90 inhibition and open possibilities for the detection of potential response biomarkers which will be essential to maximize treatment efficacy in lung adenocarcinoma.es_ES
dc.description.sponsorshipL.P.A. was funded by the Comunidad de Madrid, CAM, (B2017/BMD3884), ISCIII (PIE15/00076, PI17/00778 and DTS17/00089) and CIBERONC (CB16/12/00442), and co-funded by FEDER from Regional Development European Funds (European Union). S.M.P. is funded by the Fundación Mutua Madrileña (2014) Ministry of Health and SocialWelfare of Junta de Andalucía (PI-0046-2012, Nicolas Monardes Program C-0040-2016),ISCIII (PI17/00033), and co-funded by FEDER from Regional Development European Funds (European Union). I.F. is funded by the AECC (AIO2015) and ISCIII (PI16/01311), and co-funded by FEDER from Regional Development European Funds (European Union). AC was funded by grants from the Spanish Ministry of Economy and Competitiveness Plan Estatal de I+D+I 2018 co-funded by FEDER: RTI2018-097455-B-I00; CIBER de Cáncer Cells 2019, 8, 806 17 of 22(CB16/12/00275), co-funded by FEDER from Regional Development European Funds. Especial thanks to the Fundación AECC. L.O. is funded by the Ministerio de Educación, Cultura y Deporte (FPU13/02595).es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectHSP90 inhibitorses_ES
dc.subjectChaperoneses_ES
dc.subjectLung canceres_ES
dc.subjectProteomices_ES
dc.titleImpact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometryes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID31370342es_ES
dc.format.volume8es_ES
dc.format.number8es_ES
dc.format.page806es_ES
dc.identifier.doi10.3390/cells8080806es_ES
dc.contributor.funderComunidad de Madrid 
dc.contributor.funderEuropean Regional Development Fund 
dc.contributor.funderFundación Mutua Madrileña 
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderMinisterio de Ciencia e Innovación (España) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn2073-4409es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/cells8080806.es_ES
dc.identifier.journalCellses_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIOes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PIE15/00076es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/00778es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI-0046-2012es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/00033es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01311es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional